MSB 2.70% 95.0¢ mesoblast limited

Back Pain Results, page-26

  1. 349 Posts.
    lightbulb Created with Sketch. 7
    The macbank statement on the back pain trial stated that it was largely negative.How can they state this without issueing further evidence to substantiate that claim.The lower back trial was based on pain and functional improvement and interventions and not on Anatomical structures as macbank have stated in part of there report.They should explain the trial based evidence on Anatomical negatives if there were any to share holders before making such a claim. Overall the trial had a good success rate as per the trial outcomes.The mesoblast statement claimed that there was an improvement in the Anatomical structure.The trial also enrolled patients who were beyond help after using refractory steroids.Phase 3 on the way.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
95.0¢
Change
0.025(2.70%)
Mkt cap ! $1.084B
Open High Low Value Volume
94.0¢ 96.8¢ 93.5¢ $4.207M 4.417M

Buyers (Bids)

No. Vol. Price($)
3 42268 94.0¢
 

Sellers (Offers)

Price($) Vol. No.
95.0¢ 48002 3
View Market Depth
Last trade - 16.10pm 09/08/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.